Assessment of the antinociceptive effects of cannabinoid receptor agonists SER 601 and L-759,633 in an acute pain model in rats

Zıad Joha; Şahin Yıldırım; Bülent Saraç

doi:10.7197/cmj.870286

Research Article

Assessment of the antinociceptive effects of cannabinoid receptor agonists SER 601 and L-759,633 in an acute pain model in rats

Year 2021, Volume: 43 Issue: 1, 41 - 48, 31.03.2021

Zıad Joha Şahin Yıldırım Bülent Saraç

https://doi.org/10.7197/cmj.870286

Abstract

A poorly managed pain is associated with many negative results. These results disturb patients, their families and societies. Although opioid agents have extraordinary analgesic efficacy, they may cause serious adverse consequences. For medication of pain, there is a medical need to discover possible alternatives to opioids. In animal models of acute pain synthetic cannabinoid receptor agonists demonstrated analgesic effects. Selective activation of the cannabinoid 2 receptor in the rodent models does not cause psychotropic effects therefore CB2R agonists are an appealing target for the medication of pain and other pathologies. In this study we examined the antinociceptive activity of cannabinoid receptor 2 (CB2) agonists SER 601 and L-759,633 in different doses in rat models of acute pain using the hot plate and tail flick tests. These two agents exhibited dose-dependent antinociceptive effects in acute pain model. The analgesic effects of the administrated doses of L-759,633 and SER 601 reached their peak at 60 min. In the tail flick test, the antinociceptive effects of 3, 6 and 12 mg / kg SER601 in the acute pain were more than the L-759,633 groups at the same doses.

Keywords

Acute Pain, Cannabinoid Receptor 2 Agonists, Tail Flick, Hot Plate

Supporting Institution

Cumhuriyet University Scientific Research Project

Project Number

T-848

Thanks

This study was funded by Cumhuriyet University Scientific Research Project (T-848, Doctoral Thesis Project, CUBAP, Turkey).

References

1. Steeds CE. The anatomy and physiology of pain. Surgery. 2009;27(12):507-511. doi:10.1016/j.mpsur.2009.10.013
2. Koneti KK, Jones M. Management of acute pain. Surg (United Kingdom). 2013;31(2):77-83. doi:10.1016/j.mpsur.2012.12.004
3. Cohen SP, Mao J. Neuropathic pain: Mechanisms and their clinical implications. BMJ. 2014;348. doi:10.1136/bmj.f7656
4. Khan A, Khan S, Kim YS. Insight into Pain Modulation: Nociceptors Sensitization and Therapeutic Targets. Curr Drug Targets. 2019;20(7):775-788. doi:10.2174/1389450120666190131114244
5. Katz N. The impact of pain management on quality of life. In: Journal of Pain and Symptom Management. Vol 24. J Pain Symptom Manage; 2002. doi:10.1016/S0885-3924(02)00411-6
6. Starowicz K, Finn DP. Cannabinoids and Pain: Sites and Mechanisms of Action. In: Advances in Pharmacology. Vol 80. Academic Press Inc.; 2017:437-475. doi:10.1016/bs.apha.2017.05.003
7. Koob GF. The neurobiology of addiction: A neuroadaptational view relevant for diagnosis. Addiction. 2006;101(SUPPL. 1):23-30. doi:10.1111/j.1360-0443.2006.01586.x
8. Yuill MB, Hale DE, Guindon J, Morgan DJ. Anti-nociceptive interactions between opioids and a cannabinoid receptor 2 agonist in inflammatory pain. Mol Pain. 2017;13. doi:10.1177/1744806917728227
9. Pertwee RG. Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacol Ther. 1997;74(2):129-180. doi:10.1016/S0163-7258(97)82001-3
10. Pacher P, Kunos G. Modulating the endocannabinoid system in human health and disease - Successes and failures. FEBS J. 2013;280(9):1918-1943. doi:10.1111/febs.12260
11. Tanda G, Goldberg SR. Cannabinoids: Reward, dependence, and underlying neurochemical mechanisms - A review of recent preclinical data. Psychopharmacology (Berl). 2003;169(2):115-134. doi:10.1007/s00213-003-1485-z
12. Deng L, Guindon J, Cornett BL, Makriyannis A, Mackie K, Hohmann AG. Chronic cannabinoid receptor 2 activation reverses paclitaxel neuropathy without tolerance or cannabinoid receptor 1-dependent withdrawal. Biol Psychiatry. 2015;77(5):475-487. doi:10.1016/j.biopsych.2014.04.009
13. Kinsey SG, Mahadevan A, Zhao B, et al. The CB2 cannabinoid receptor-selective agonist O-3223 reduces pain and inflammation without apparent cannabinoid behavioral effects. Neuropharmacology. 2011;60(2-3):244-251. doi:10.1016/j.neuropharm.2010.09.004
14. Guindon J, Hohmann AG. Cannabinoid CB 2 receptors: A therapeutic target for the treatment of inflammatory and neuropathic pain. Br J Pharmacol. 2008;153(2):319-334. doi:10.1038/sj.bjp.0707531
15. Kanaan SA, Saadé NE, Haddad JJ, et al. Endotoxin-induced local inflammation and hyperalgesia in rats and mice: A new model for inflammatory pain. Pain. 1996;66(2-3):373-379. doi:10.1016/0304-3959(96)03068-0
16. Ramabadran K, Bansinath M, Turndorf H, Puig MM. The hyperalgesic effect of naloxone is attenuated in streptozotocin-diabetic mice. Psychopharmacology (Berl). 1989;97(2):169-174. doi:10.1007/BF00442244
17. Demirkazik A, Ozdemir E, Arslan G, Taskiran AS, Pelit A. The effects of extremely low-frequency pulsed electromagnetic fields on analgesia in the nitric oxide pathway. Nitric Oxide - Biol Chem. 2019;92:49-54. doi:10.1016/j.niox.2019.08.003
18. Ibrahim MM, Rude ML, Stagg NJ, et al. CB2 cannabinoid receptor mediation of antinociception. Pain. 2006;122(1-2):36-42. doi:10.1016/j.pain.2005.12.018
19. Malan TP, Ibrahim MM, Deng H, et al. CB2 cannabinoid receptor-mediated peripheral antinociception. Pain. 2001;93(3):239-245. doi:10.1016/S0304-3959(01)00321-9
20. Hanuš L, Breuer A, Tchilibon S, et al. HU-308: A specific agonist for CB2, a peripheral cannabinoid receptor. Proc Natl Acad Sci U S A. 1999;96(25):14228-14233. doi:10.1073/pnas.96.25.14228
21. Valenzano KJ, Tafesse L, Lee G, et al. Pharmacological and pharmacokinetic characterization of the cannabinoid receptor 2 agonist, GW405833, utilizing rodent models of acute and chronic pain, anxiety, ataxia and catalepsy. Neuropharmacology. 2005;48(5):658-672. doi:10.1016/j.neuropharm.2004.12.008
22. Rezaee-Asl M, Sabour M, Nikoui V, Ostadhadi S, Bakhtiarian A. The Study of Analgesic Effects of Leonurus cardiaca L. in Mice by Formalin, Tail Flick and Hot Plate Tests . Int Sch Res Not. 2014;2014:1-5. doi:10.1155/2014/687697
23. Fan SH, Ali NA, Basri DF. Evaluation of analgesic activity of the methanol extract from the galls of quercus infectoria (Olivier) in Rats. Evidence-based Complement Altern Med. 2014;2014. doi:10.1155/2014/976764